Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate

Lantern Pharma Inc.

2025-Q3 EPS reported -$1.21

Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.
LP-184 Phase 1a met all endpoints; 48% clinical benefit rate at therapeutic dose; RP2D set at 0.39 mg/kg.
FDA Type C meeting provides regulatory path for pediatric CNS trial in ATRT; spironolactone combo strategy confirmed.
LP-300 HARMONIC trial data presented at Japan Lung Cancer Society; Japan enrollment completed.
RADR AI platform modules commercial-ready; predictBBB 94.1% accuracy, LBx-AI 86% accuracy for treatment response.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.